Vikram Raghunathan

735 total citations
13 papers, 455 citations indexed

About

Vikram Raghunathan is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Vikram Raghunathan has authored 13 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Hematology, 3 papers in Genetics and 2 papers in Molecular Biology. Recurrent topics in Vikram Raghunathan's work include Hemoglobinopathies and Related Disorders (3 papers), Platelet Disorders and Treatments (2 papers) and Iron Metabolism and Disorders (2 papers). Vikram Raghunathan is often cited by papers focused on Hemoglobinopathies and Related Disorders (3 papers), Platelet Disorders and Treatments (2 papers) and Iron Metabolism and Disorders (2 papers). Vikram Raghunathan collaborates with scholars based in United States and South Africa. Vikram Raghunathan's co-authors include Joseph J. Shatzel, Thomas G. DeLoughery, Sven R. Olson, Emerson Y. Chen, Vinay Prasad, Hanny Al‐Samkari, Seah H. Lim, Patrycja M. Dubielecka, Nga Nguyen and Baldeep Wirk and has published in prestigious journals such as Blood, JAMA Internal Medicine and Journal of Translational Medicine.

In The Last Decade

Vikram Raghunathan

11 papers receiving 441 citations

Peers

Vikram Raghunathan
Ashraf Mikhail United Kingdom
Raja I. Zabaneh United States
Jeffrey A. Gilreath United States
Heikki Relas Finland
Melanie Blank United States
Ashraf Mikhail United Kingdom
Vikram Raghunathan
Citations per year, relative to Vikram Raghunathan Vikram Raghunathan (= 1×) peers Ashraf Mikhail

Countries citing papers authored by Vikram Raghunathan

Since Specialization
Citations

This map shows the geographic impact of Vikram Raghunathan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vikram Raghunathan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vikram Raghunathan more than expected).

Fields of papers citing papers by Vikram Raghunathan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vikram Raghunathan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vikram Raghunathan. The network helps show where Vikram Raghunathan may publish in the future.

Co-authorship network of co-authors of Vikram Raghunathan

This figure shows the co-authorship network connecting the top 25 collaborators of Vikram Raghunathan. A scholar is included among the top collaborators of Vikram Raghunathan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vikram Raghunathan. Vikram Raghunathan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Poh, Christina, Jenna Voutsinas, Mazyar Shadman, et al.. (2025). Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas. Blood Advances. 9(15). 4037–4042. 1 indexed citations
3.
Ujjani, Chaitra S., Christina Poh, Edus H. Warren, et al.. (2024). Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma. Blood. 144(Supplement 1). 1667–1667. 1 indexed citations
4.
Lynch, Ryan C., Stefan Alig, Chaitra S. Ujjani, et al.. (2024). High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD. Blood. 144(Supplement 1). 3051–3051.
5.
Nguyen, Nga, et al.. (2020). Diagnosis and management of hereditary haemochromatosis. Vox Sanguinis. 115(4). 255–262. 29 indexed citations
6.
Oakes, Michael, et al.. (2020). The Prevalence and Management of Secondary Erythrocytosis in Transgender Individuals Undergoing Masculinizing Therapy. Blood. 136(Supplement 1). 13–13. 1 indexed citations
7.
Raghunathan, Vikram, et al.. (2019). Long‐term remission rates after splenectomy in adults with Evans syndrome compared to immune thrombocytopenia: A single‐center retrospective study. European Journal Of Haematology. 104(1). 55–58. 8 indexed citations
8.
Chen, Emerson Y., Vikram Raghunathan, & Vinay Prasad. (2019). An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate. JAMA Internal Medicine. 179(7). 915–915. 102 indexed citations
9.
Olson, Sven R., et al.. (2019). The role of iron repletion in adult iron deficiency anemia and other diseases. European Journal Of Haematology. 104(3). 153–161. 103 indexed citations
10.
Olson, Sven R., et al.. (2019). The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients. European Journal Of Haematology. 104(2). 79–87. 143 indexed citations
11.
Lim, Seah H., Patrycja M. Dubielecka, & Vikram Raghunathan. (2017). Molecular targeting in acute myeloid leukemia. Journal of Translational Medicine. 15(1). 183–183. 36 indexed citations
12.
Raghunathan, Vikram, et al.. (2017). Sleep-disordered breathing in patients with sickle cell disease. Annals of Hematology. 97(5). 755–762. 22 indexed citations
13.
Raghunathan, Vikram, et al.. (2017). Gastrointestinal Tract Amyloidosis Presenting With Pneumatosis Intestinalis. Journal of Clinical Medicine Research. 9(7). 654–658. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026